Q-omics provides the consensus-scored RPL12P1 profile across patient tissues and cancer cell-line models. RPL12P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL12P1 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, RPL12P1 RNA expression shows 10,025 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LUAD as cancer lineages where RPL12P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL12P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL12P1 survival associations across molecular data types. RPL12P1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL12P1 RNA expression–survival associations across cancer types. High RPL12P1 expression shows unfavorable associations in ACC, KIRP and LGG, but favorable associations in UCS, BLCA and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL12P1 RNA expression.
This table summarizes RPL12P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL12P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL12P1 shows higher tumor expression in LUAD, LUSC, BLCA, BRCA, COAD and HNSC. The LUAD box plot shows higher RPL12P1 RNA expression in tumor versus normal tissue (log2 FC = +0.272, t-test p < 0.001).
This table shows molecular features associated with RPL12P1 in patient tissues and cancer cell lines. In patient samples, RPL12P1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
